TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. In the past two years, the focus has been on its commercial strategy, restructuring to service demand, and commencing a capacity expansion programme in its US facilities. Phase 1 of the expansion programme has been completed, which, together with the potential return of elective surgeries following the pandemic, positions TRX well for growth and profitability.
30 Jun 2021
Poised for growth
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Poised for growth
Tissue Regenix Group plc (TRX:LON) | 61.5 0 0.0% | Mkt Cap: 43.4m
- Published:
30 Jun 2021 -
Author:
Martin Hall -
Pages:
20
TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. In the past two years, the focus has been on its commercial strategy, restructuring to service demand, and commencing a capacity expansion programme in its US facilities. Phase 1 of the expansion programme has been completed, which, together with the potential return of elective surgeries following the pandemic, positions TRX well for growth and profitability.